Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TPI ASM8 in Asthma
NCT01158898Phase 2Completed
- Sponsor
- Syntara Limited
- Start
- Nov 2010
- Primary completion
- Dec 2011
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASM8 in asthma (3 arms), sponsored by Syntara Limited. Primary endpoint: Area Under the Curve of the Late Asthmatic Response at Day 14. Started Nov 2010; status: completed.
02
Drugs
ASM8
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01158898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01158898.